Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4264
Source ID: NCT01526941
Associated Drug: Biphasic Insulin Aspart 30
Title: Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1
Interventions: DRUG: biphasic insulin aspart 30|DRUG: biphasic insulin aspart 70
Outcome Measures: Primary: Steady state area under the glucose infusion rate profile, 6-12 hours | Secondary: GIRmax, the maximal glucose infusion rate value|tmax, time to maximum glucose infusion rate value|area under the glucose infusion rate profile|Time to 50% of area under the glucose infusion rate profile, 0-12 hours|Cmax, maximum concentration|tmax, time to reach Cmax|Area under the curve|t½, terminal half-life|Adverse events
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 27
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2001-05
Completion Date: 2001-07
Results First Posted:
Last Update Posted: 2017-01-05
Locations: Novo Nordisk Investigational Site, Neuss, 41460, Germany
URL: https://clinicaltrials.gov/show/NCT01526941